Dr Michael Hammerbacher, AUD in Robins Afb, GA - Audiologist

Dr Michael Hammerbacher, AUD is a Audiologist based in Robins Afb, Georgia. Dr Michael Hammerbacher is licensed to practice in Texas (license number 80729) and his current practice location is 655 7th St, Robins Afb, Georgia. He can be reached at his office (for appointments etc.) via phone at (478) 327-8487.

NPI number for Dr Michael Hammerbacher is 1841683398 and his current mailing address is 655 7th St, Robins Afb, Georgia. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1841683398.

Contact Information

	Dr Michael Hammerbacher, AUD
	655 7th St, Robins Afb, GA 31098-2227
	(478) 327-8487
	Not Available

Healthcare Provider's Profile

Full Name	Dr Michael Hammerbacher
Gender	Male
Speciality	Audiologist
Location	655 7th St, Robins Afb, Georgia
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1841683398
Provider Enumeration Date: 03/09/2015
Last Update Date: 09/13/2023

Medical Identifiers

Medical identifiers for Dr Michael Hammerbacher such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1841683398	NPI	-	NPPES
1841683398	Other		MILITARY

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
231H00000X	Audiologist	80729 (Texas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Michael Hammerbacher is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Michael Hammerbacher, AUD 655 7th St, Robins Afb, GA 31098-2227 Ph: (478) 327-8487	Dr Michael Hammerbacher, AUD 655 7th St, Robins Afb, GA 31098-2227 Ph: (478) 327-8487

News Archive

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey.

Study: Most pediatric cancer patients have mild COVID-19 and make full recovery

Most children and adolescents with cancer have mild COVID-19 disease and make a full recovery, a new study has found. But pediatric cancer patients with underlying health conditions, severe infections and low white blood cell counts were significantly more likely to have severe disease.

Dialysis extension at Atlanta hospital eases crisis for illegal immigrants

The New York Times: "In early October, when Grady, Atlanta's public hospital, closed its outpatient dialysis unit for budgetary reasons, it agreed to pay for three months of dialysis at private clinics for about 50 dislocated patients.

Dr Michael Hammerbacher, AUD - Audiologist in Robins Afb, GA